The report sheds light on some of the most influential developments in the field between June 2016 and May 2017. These include St. Jude Medical’s expansion into the heart failure portfolio with the introduction of SyncAV cardiac resynchronisation therapy technology, FDA’s approval for Medtronic cardiac devices to grant patients access to advanced diagnostic imaging, US Department of Veterans Affairs’ national contract awarded to Medtronic in the field of home telehealth, Medtronic CRT devices proven cost-effective in new assessment of reverse trial, and US FDA approval for Boston Scientific’s line of high-voltage devices.
The various products currently in the pipeline find a special mention in the research report on the cardiac resynchronisation therapy market. An overview of ongoing clinical trials conducted by each of the companies profiled in the report has also been provided. For instance, the pipeline products for Boston Scientific – Autogen X4 CRT-D, Next Generation Quad Polar CRT-D, CHARISMA X4, and NG3 Non Quad System – are studied based on product description and status.
Other products reviewed in the report on the cardiac resynchronisation therapy market are: Cardiac Arrhythmia Termination Device by John Hopkins University; Paradym CRT-D Tri-V Device, Paradym RF SonR CRT-D, Paradym RF Platform, and Triple-Site Ventricular (Tri-V) Pacing CRT-D by LivaNova PLC; Atrial Fibrillation Device by Mayo Clinic US; Amplia MRI Quad CRT-D SureScan System, Claria MRI Quad CRT-D SureScan System, and MRI Safe CRT-D by Medtronic plc; Implantable Subcutaneous String Defibrillator (ISSD) by NewPace Ltd.; Quadra Assura MP CRT-D by St. Jude Medical LLC; and Soul Mate Defibrillator by TransWorld Med Corp.
These pipeline products are analyzed on a comparative basis, depending on the various stages of their development. Information with respect to the many clinical trials in progress has also been provided, offering details such as number of trials, trial status, trial phase, and trial start and end dates.
Some of the major contributors toward the growth of the cardiac resynchronisation therapy market are St. Jude Medical LLC, Mayo Clinic US, John Hopkins University, NewPace Ltd., Medtronic plc, IRadimed Corp., LivaNova PLC, Boston Scientific Corp., and TransWorld Med Corp. The report studies the product pipeline for each company and ongoing clinical trials. A comprehensive overview of each profiled players has also been provided.